Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Price, Not Safety, Most Likely To Limit Avastin Use In Breast Cancer – JPMorgan Physician Survey

This article was originally published in The Pink Sheet Daily

Executive Summary

Long-term revenue upside for drug in all indications could be as much as $6.5 billion by 2012, says JPMorgan analyst Geoffrey Meacham.

You may also be interested in...

Genentech Watchers Weigh Deeper Meaning Of Avastin’s Approval

FDA’s breast-cancer decision not a universal surprise, and there’s still risk in RIBBON-1.

“Creative” FDA Clears Avastin For First-Line Breast Cancer

Accelerated approval wants more clinical proof.

Genentech’s Top-Line AVADO Data Strong With Avastin For Breast Cancer

Though not registrational, study could bolster NDA package.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts